MedCap AB (61MA) AI Stock Analysis

1 Followers

MedCap AB

(Frankfurt:61MA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitable revenue growthPositive revenue expansion alongside healthy EBIT, EBITDA, and net margins indicates that MedCap’s portfolio companies are converting growth into substantial operating profitability. This supports reinvestment, strengthens the earnings base, and suggests the group has durable economic value beyond short-term sales fluctuations.

Negative Factors

Uneven operating cash conversionAlthough free cash flow is generally good, weaker and uneven operating cash conversion means earnings may not consistently arrive as cash within the same periods. This can create working-capital volatility, complicate portfolio funding decisions, and reduce flexibility during periods of faster investment or weaker trading.

MedCap AB (61MA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 754.29M
Dividend Yield: ―
Average Volume (3M): 6
Price to Earnings (P/E): 30.4
Beta (1Y): 0.29
Revenue Growth: 19.59%
EPS Growth: 42.34%
Country: Germany
Employees: 647
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

MedCap AB Business Overview & Revenue Model

Company Description

MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature b...

MedCap AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:61MA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SECT.B	74Outperform	SEK 62.79B	98.41	30.26%	0.71%	13.94%	5.70%
SE:GETI.B	67Neutral	SEK 76.70B	27.10	9.13%	1.69%	-3.90%	37.73%
SE:XVIVO	64Neutral	SEK 6.49B	50.37	5.89%	―	17.83%	330.94%
SE:VITR	63Neutral	SEK 16.15B	-3.26	-61.57%	0.92%	-1.94%	-1223.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SEDANA	49Neutral	SEK 907.94M	-26.31	-3.88%	―	0.42%	15.03%

* Healthcare Sector Average

Performance Comparison

DE:61MA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:61MA	MedCap AB	49.70	0.85	1.74%
SE:GETI.B	Getinge AB (UK)	281.60	74.49	35.96%
SE:VITR	Vitrolife AB	119.20	-22.34	-15.79%
SE:XVIVO	Xvivo Perfusion AB	206.00	42.50	25.99%
SE:SECT.B	Sectra AB Class B	321.80	36.48	12.78%
SE:SEDANA	Sedana Medical AB	9.14	-0.37	-3.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

MedCap AB AI Stock Analysis